ABSTRACT
【Objective】 To investigate the effect and prognosis of Roxastat combined with levocarnitine and polysaccharide iron complex in patients with chronic renal failure hemodialysis anemia(CRFHA). 【Methods】 A total of 70 patients with CRFHA treated in our hospital from January 2019 to December 2020 were selected as study subjects. They were divided into control group and treatment group by simple randomizaiton grouping method. After 5 cases in each group dropped out due to transfer, COVID-19 epidemic and missed follow-up, 30 cases were left in each group.The control group was treated with Roxastat, and the treatment group with L-carnitine and polysaccharide iron complex based on Roxastat. The differences in anemia parameters, iron metabolism, dialysis-related indexes and complications between the two groups were observed and compared. 【Results】 After 3 months of treatment, Hb, RBC, Hct, TIBC, FE, and FERR in the treatment group were significantly higher than those in the control group (118.36±6.64 vs 109.34±6.25, 4.32±0.264 vs 4.03±0.32, 32.37±3.30 vs 29.85±3.24, 67.62±10.66 vs 62.78±10.32, 17.87±3.81 vs 12.51±3.82, 389.37±18.30 vs 362.85±18.04, respectively, P0.05). Blood creatinine of patients after 3 months of treatment was significantly higher (control group: 1 016.27±122.14 vs 1 052.27±96.23; observation group 1 014.23±121.57 vs 1 056.25±96.82, P<0.05); blood phosphorus (control group: 2.21±0.21vs 2.14±0.21; observation group: 2.23±0.30 vs 2.15±0.64) was significantly lower(P<0.05); blood calcium (control group: 2.07±0.51 vs 1.85±0.54; observation group 2.05±0.50 vs 1.87±0.52) was significantly lower (P<0.05 ). A comparison of complications between the two groups of patients after 6 months of treatment showed that the combined incidence of gastrointestinal function, increased blood pressure, and fever in the treatment group was lower than that in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】 Roxastat combined with L-carnitine and polysaccharide iron complex in patients with CRFHA has definite effect, which improves dialysis-related indicators, has great advantages in optimizing anemia parameters and iron metabolism, and provides reference value for clinical treatment of CRFHA
ABSTRACT
OBJECTIVE:To compare the clinical efficacy and safety of Jianpi shengxue tablets and Iron polysaccharide complex capsules in the treatment of nondialysis renal anemia. METHODS:A total of 60 nondialysis renal anemia patients in our hospital during Mar. 2016 to Mar. 2017 were divided into control group(30 cases)and observation group(30 cases)with random allocation concealment method according to random number and admission order. Both groups received routine treatment as rhEPO injection,Folic acid tablets,Vitamin B12 tablets. Based on it,control group was given Iron polysaccharide complex capsules 0.15 g orally,once a day;observation group was given Jianpi shengxue tablets 1.8 g orally,3 times a day. Both groups were treated for 12 weeks. Clinical efficacies were compared between 2 groups. The levels of Hb,RBC,HCT and Ret％ were observed before treatment and 2,4,8,12 weeks after treatment;the levels of SI,SF and TS were also observed before treatment and 8,12 weeks after treatment. The occurrence of ADR was recorded. RESULTS:Both groups completed the treatment. The total effective rate of observation group(86.67％)was significantly higher than control group(63.33％),with statistical significance(P<0.05). Before treatment,there was no statistical significance in the levels of Hb,RBC,HCT,Ret％,SI,SF or TS between 2 groups (P<0.05). After treatment,the levels of above indexes in 2 groups were significantly higher than before treatment,and observation group was significantly higher than control group(except for Ret％ at 8th week),with statistical significance(P<0.05). The case number of black stool and rust colored stool in observation group were significantly lower than control group,while the incidence of black-dyed teeth in observation group was significantly higher than control group, with statistical significance (P<0.05). CONCLUSIONS:Therapeutic efficacy of Jianpi shengxue tablets are significantly better than Polysaccharide iron complex capsules in the treatment of nondialysis renal anemia,and can significantly improve iron reserve and anaemia. But Jianpi shengxue tablets causes high incidence of black-dyed teeth.
ABSTRACT
Objective: To observe the anemia situation and pregnancy outcome of pregnant women with iron deficiency anemia ( IDA) treated with polysaccharide iron complex. Methods:Totally 102 patients with IDA were randomly divided into the control group (51 cases) and the study group (51 cases). The control group was treated with iron dextran tablets orally, and the study group re-ceived polysaccharide iron complex. The improvement of anemia and the pregnancy outcome were compared, and the adverse reactions were recorded. Results:After the treatment, hemoglobin ( Hb) , serum iron ( SI) , serum ferritin ( SF) and serum transferrin receptor ( sTfR) at 24-week pregnancy and before the delivery, the red cell count ( RBC) and mean corpuscular hemoglobin ( MCH) before the delivery in the study group were all better than those in the control group (P<0. 05). The incidence of adverse reactions in the two groups was similar. Conclusion:Polysaccharide iron complex can improve anemia status of pregnant women with IDA, which is worthy of widely clinical use.
ABSTRACT
OBJECTIVE:To investigate the effect and cost of Multidimensional iron oral liquid and Polysaccharide iron com-plex capsules in the treatment of iron deficiency anemia during pregnancy. METHODS:By retrospective study,80 cases of iron de-ficiency anemia during pregnancy were divided into control group and trial group in accordance to different therapy plans,with 40 cases in each group. Control group was given Multidimensional iron oral liquid orally,10 ml each time,bid,after breakfast and supper,for consecutive 4 weeks;trial group was given Polysaccharide iron complex capsules orally,0.30 g each time,qd,for con-secutive 4 weeks. Clinical efficacy,erythrocyte related lab indexes,satisfactory rate and ADR were compared between 2 groups, and cost-effectiveness analysis was adopted for economic evaluation. RESULTS:The total effective rate of experimental group was 95.0%,which was higher than 85.0% of control group,but without statistical significance(P>0.05);hemoglobin level,erythro-cyte count and average volume of erythrocyte of trial group were significantly higher or more than control group,and satisfactory rate(95.0% vs. 65.0%)were significantly higher than control group,with statistical significance(P<0.05);no obvious ADR was found in 2 groups. Total cost of trial group and control group were 243.60 and 166.32 yuan,and cost-effective ratio was 2.56 and 1.96;incremental cost-effective ratio was 7.73. Results of sensitivity analysis were same to the result. CONCLUSIONS:Both Multi-dimensional iron oral liquid and Polysaccharide iron complex capsules can improve anemia in patients with iron deficiency anemia during pregnancy. Polysaccharide iron complex capsules show better therapeutic efficacy and satisfactory rate,but it is relatively ex-pensive. Drugs should be selected according to economic situation.